Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07639723 · ClinicalTrials.gov registry record · Phase 4
Aprepitant to Improve Same Day Discharge for TKA
A Phase 4 study, sponsored by Endeavor Health.
- Not yet
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
NCT07639723: Clinical Trial Phase 4 study, sponsored by Endeavor Health.
NCT07639723 is a Phase 4 study that has not yet begun recruiting, run by Endeavor Health. The registered enrollment target is 350 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07639723, a Phase 4 study, has not yet begun recruiting, sponsored by Endeavor Health.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
Study Summary
The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.
Primary Outcome
difference in the incidence of same-day discharges between two randomized groups of anti-emetic regimens for anesthesia care. Subjects will be randomized to either the aprepitant group (administration of aprepitant, ondansetron, and dexamethasone) or control (ondansetron, dexamethasone, and placebo). PACU and ASU staff will collect real time data with regard to the primary and secondary reason for any hospital admission (PONV, Pain control, Rapid response team called, Vital sign abnormalities, C
Interventions
- OTHER Placebo
- DRUG Dexamethasone
- DRUG Ondansetron (Zofran)
- DRUG Aprepitant Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
What is known before NCT07639723 opens enrollment
NCT07639723 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07639723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07639723 about?
NCT07639723 is a clinical study titled "Aprepitant to Improve Same Day Discharge for TKA". The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more...
What is the current status of trial NCT07639723?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2026-07. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07639723?
The interventions under investigation include: Placebo (OTHER), Dexamethasone (DRUG), Ondansetron (Zofran) (DRUG), Aprepitant Injection (DRUG).
Who is sponsoring clinical trial NCT07639723?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07639723's enrollment target sits among peer trials
350 231st of 2000 higher than 1,761 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia